

# Jaime R Merchan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12122693/publications.pdf>

Version: 2024-02-01

40  
papers

5,019  
citations

471509

17  
h-index

377865

34  
g-index

40  
all docs

40  
docs citations

40  
times ranked

6061  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.	27.0	1,648
2	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2516.	7.4	1,111
3	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	27.0	956
4	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 837-848.	10.7	262
5	A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. <i>BMC Cancer</i> , 2012, 12, 199.	2.6	198
6	Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 342-348.	0.5	100
7	A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 151-156.	1.3	94
8	Antiangiogenic Activity of 2-Deoxy-D-Glucose. <i>PLoS ONE</i> , 2010, 5, e13699.	2.5	92
9	Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibition. <i>International Journal of Cancer</i> , 2005, 113, 490-498.	5.1	79
10	Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. <i>Pancreatology</i> , 2015, 15, 667-673.	1.1	73
11	Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor. <i>Cancer Research</i> , 2009, 69, 1459-1468.	0.9	64
12	Targeted Measles Virus Vector Displaying Echistatin Infects Endothelial Cells via $\alpha_5\beta_1$ and Leads to Tumor Regression. <i>Cancer Research</i> , 2005, 65, 5292-5300.	0.9	63
13	In Vitro and In Vivo Induction of Antiangiogenic Activity by Plasminogen Activators and Captopril. <i>Journal of the National Cancer Institute</i> , 2003, 95, 388-399.	6.3	55
14	Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1410-1420.	3.4	27
15	2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3 $\beta$ Activation. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 264-275.	4.1	26
16	A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 106-106.	1.6	22
17	Targeting tumor vasculature through oncolytic virotherapy: recent advances. <i>Oncolytic Virotherapy</i> , 2015, 4, 169.	6.0	19
18	Role of Plasminogen Activator Inhibitor-1 in Urokinase's Paradoxical <i>In Vivo</i> Tumor Suppressing or Promoting Effects. <i>Molecular Cancer Research</i> , 2012, 10, 1271-1281.	3.4	17

#	ARTICLE	IF	CITATIONS
19	Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. <i>Molecular Carcinogenesis</i> , 2013, 52, 218-228.	2.7	17
20	Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 446-450.	1.3	16
21	Preclinical safety and activity of recombinant VSV $\Delta$ g $\Delta$ FN $\Delta$ in an immunocompetent model of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2014, 36, 1619-1627.	2.0	14
22	Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 485-493.	2.3	14
23	Antiangiogenic property of human thrombin. <i>Microvascular Research</i> , 2003, 66, 1-14.	2.5	13
24	The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 135-139.	1.4	11
25	Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6024-6024.	1.6	8
26	A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3209-3217.	7.0	5
27	Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4533-4533.	1.6	5
28	Percutaneous irreversible electroporation (IRE) in the management of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15249-e15249.	1.6	2
29	Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 413-413.	1.6	2
30	Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b.. <i>Journal of Clinical Oncology</i> , 2017, 35, 445-445.	1.6	2
31	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5063-5063.	1.6	1
32	Results of a phase 1 study of single agent RX-3117: An oral antimetabolite nucleoside to treat solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2555-2555.	1.6	1
33	Preclinical study of cytotoxicity and predictive markers of response to dual inhibition of PI3K and mTORC1/2 signaling by NVP-BE2235 with or without paclitaxel or nab-paclitaxel as a new therapeutic strategy in pancreatic cancer cell lines.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15007-e15007.	1.6	1
34	Prevalence of radiologic evidence of metastatic pancreatic ductal adenocarcinoma (PDAC) at first post-operative restaging studies in patients (pts) undergoing pancreatic cancer surgery with curative intent.. <i>Journal of Clinical Oncology</i> , 2016, 34, 225-225.	1.6	1
35	Long-term response in a patient with urothelial cancer (UC) treated with AEZS-108.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15596-e15596.	1.6	0
36	Phase 1 trial of zoptarelin doxorubicin (Zop-Dox) in advanced unresectable or metastatic urothelial carcinoma (UC) patients who failed platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15517-e15517.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Updated survival analysis of patients (pts) with unresectable (UR) or borderline resectable (BR) locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX.. Journal of Clinical Oncology, 2014, 32, e15197-e15197.	1.6	0
38	The value of tissue protein expression as a predictor of efficacy for first- or second-line therapy (tx) in metastatic ductal pancreas cancer (PDAC) in patients (pts) receiving either gemcitabine (G)-based tx or 5FU (F)-based tx.. Journal of Clinical Oncology, 2015, 33, 460-460.	1.6	0
39	Exploring phosphatase and tensin homolog (PTEN) loss via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) as a potential predictive marker for response to everolimus in patients (pts) with neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2015, 33, 333-333.	1.6	0
40	The evolving landscape of oncolytic virotherapy (OV) clinical trials (CT): Meta-analysis.. Journal of Clinical Oncology, 2017, 35, e14636-e14636.	1.6	0